Cargando…

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers

It is well documented that human epidermal growth factor receptor 2 (HER2) overexpression/amplification is associated with poor survival in breast cancer patients. However, it is largely unknown whether HER2 somatic mutations are associated with survival in HER2‐negative breast cancer patients. Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Tonghui, Xu, Ye, Sheng, Shuyan, Yuan, Hua, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xie, Yuntao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406600/ https://www.ncbi.nlm.nih.gov/pubmed/28164408 http://dx.doi.org/10.1111/cas.13182

Ejemplares similares

Germline mutation in DNA‐repair genes is associated with poor survival in BRCA1/2‐negative breast cancer patients
por: Fan, Zhenhua, et al.
Publicado: (2019)

Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA‐negative breast cancers
por: Xu, Ye, et al.
Publicado: (2017)

Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients
por: Xu, Huiying, et al.
Publicado: (2018)

Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer
por: Wan, Qiting, et al.
Publicado: (2021)

Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer
por: Liu, Yin, et al.
Publicado: (2015)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer
por: Sun, Jie, et al.
Publicado: (2015)

A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients
por: Wu, Lina, et al.
Publicado: (2015)

Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial
por: Yang, Yang, et al.
Publicado: (2023)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial
por: Yang, Yang, et al.
Publicado: (2023)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

Feasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel lymph node metastasis in breast cancer patients
por: Chen, Xue, et al.
Publicado: (2018)

Impact of Sentinel Lymph Node Biopsy on Treatment Decision and Survival in Patients Aged ≥70 Years with Breast Cancer: A Retrospective Study
por: Gu, Chongshan, et al.
Publicado: (2022)

HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2‐negative patients
por: Si, Pilei, et al.
Publicado: (2017)

Impact of clinical and pathological factors on local recurrence after breast-conserving treatment: CT-based localization for a tumor bed boost yielded better local control when compared with a surgical scar
por: Wang, Lize, et al.
Publicado: (2019)

Ultrasound as a replacement for physical examination in clinical staging of axillary lymph nodes in breast cancer patients
por: Chen, Xue, et al.
Publicado: (2019)

Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients
por: Guo, Yonghai, et al.
Publicado: (2022)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Early prediction of pathological outcomes to neoadjuvant chemotherapy in breast cancer patients using automated breast ultrasound
por: Wang, Xinguang, et al.
Publicado: (2016)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021)

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer
por: Glynn, Sharon A, et al.
Publicado: (2010)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
por: Tovey, S M, et al.
Publicado: (2009)

A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
por: Yang, Yuqin, et al.
Publicado: (2022)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

TIMAP Upregulation Correlates Negatively with Survival in HER2- Negative Subtypes of Breast Cancer
por: Obeidat, Marya, et al.
Publicado: (2021)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Effect of Local Versus General Anesthesia in Breast-Conserving Surgery on Cancer Recurrence and Cost
por: Gu, Chongshan, et al.
Publicado: (2022)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
por: Van Bockstal, Mieke R., et al.
Publicado: (2020)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Interaction between HER2 and ATM predicts poor survival in bladder cancer patients
por: Albarakati, Nada, et al.
Publicado: (2022)

A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer
por: Zhou, Yijun, et al.
Publicado: (2016)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g1hgrp5nc90n51qnoa7jaa1gm7